新华财经长沙12月2日电（记者常竣斐）"十五五"规划建议提出，推动量子科技、生物制造、氢能和核 聚变能、脑机接口、具身智能、第六代移动通信等成为新的经济增长点。记者在12月1日举办的津市市 院士专家咨询委员会第三次会议暨生物制造产业创新大会上观察到，湖南津市已聚集27家生物制造核心 企业，可生产200多种高端合成生物产品，科创企业涌入，生物制造产业正加速转型升级。 慕恩（广州）生物科技有限公司2018年入选了津市市政府与广州越秀基金以"政府+基金"联合投资方式 开展的企业"育苗计划"，2020年签约落户津市后成立湖南慕恩生物科技有限公司。目前已搭建起从发现 微生物、筛选微生物、改造微生物到应用微生物的完整微生物组产业化技术体系，并成长为国际领先的 微生物组平台型技术公司，建成超32万株微生物菌种资源库。 据介绍，津市坚持"飞地研发+津市制造"，构建"科创平台—中试基地—加速工厂—产业园区"生物制造 全链条孵化体系。2023年，湖南生物制造中试基地有限公司成立，可协助企业完成氨基酸类产品、维生 素类产品和化妆类产品的中试试验，最多可同时为5个科研团队完成产品验证，今年11月入围了工信部 公示的首批生物制造中试能 ...

Group 1 - The company currently offers inositol as its vitamin product and plans to launch additional vitamin and amino acid products in the future [1]

Core Insights - In the first half of 2025, China's pharmaceutical import and export trade remained stable despite a complex external environment, with a total trade volume of $97.95 billion, a slight increase of 0.2% year-on-year [1] - Exports amounted to $54.54 billion, reflecting a year-on-year growth of 3.8%, while imports totaled $43.41 billion, showing a decline of 3.9% [1] Pharmaceutical Products Overview - The export of key pharmaceutical products such as raw materials, hospital diagnostics and treatments, disposable consumables, and Western medicine formulations continued to grow, with the main export markets, excluding the U.S., also seeing increases [1] - The decline in imports was primarily attributed to a significant drop in medical device imports across the board [1] Traditional Chinese Medicine (TCM) - The import and export volume of TCM products was $3.97 billion, down 4.6% year-on-year, with exports at $2.54 billion (down 4.3%) and imports at $1.43 billion (down 5.2%) [2] - Notable declines in export volumes were observed for key TCM products, with prices for TCM products decreasing by 23% year-on-year [2] - TCM imports showed a positive trend with a 14.9% increase, supported by favorable policies and the addition of 24 new importable TCM materials [2] Western Medicine - The import and export volume of Western medicine products remained stable, with exports at $27.93 billion (up 3.7%) and imports at $24.99 billion (down 3.9%) [3] - Raw material exports reached $27.93 billion, with a slight price decrease of 1.8%, while vitamin exports saw significant growth [3] - The export of Western medicine formulations grew by 6.5%, with notable increases in hormone and vitamin products [4] Medical Devices - Medical device exports totaled $24.1 billion, reflecting a 5% increase, while imports were $16.99 billion, down 3.9% [5] - Significant growth was noted in hospital diagnostics and treatment categories, with specific devices like artificial joints and non-invasive ventilators showing substantial increases [5][6] - However, the overall import of medical devices saw a decline, with notable drops in various categories including in vitro diagnostic reagents and X-ray equipment [6] Trade Partners and Market Dynamics - China's pharmaceutical trade involved over 190 countries, with the EU, the U.S., and ASEAN being the top three partners, accounting for 60.5% of total trade [7] - Trade with the EU and the U.S. saw declines, while trade with ASEAN and Belt and Road Initiative countries experienced growth [7][9] - The export to Belt and Road countries reached $20.77 billion, up 4.5%, indicating a growing acceptance and demand for Chinese pharmaceutical products in these markets [9] Emerging Markets - Exports to BRICS countries like Russia and Brazil showed significant growth, while imports from Latin America also increased [9] - The stability of traditional products combined with the exploration of emerging markets is becoming essential for the international development of the industry [9]

Group 1 - The stock price of Fengyuan Pharmaceutical closed at 7.50 yuan on July 29, 2025, down 1.45% from the previous trading day, with a trading range of 8.94% [1] - The company is primarily engaged in the research, production, and sales of chemical raw materials and formulations, covering various therapeutic areas including antipyretic analgesics, antibiotics, and vitamins [1] - As a key enterprise in the pharmaceutical industry of Anhui Province, Fengyuan Pharmaceutical's business involves multiple segments including raw materials, formulations, and pharmaceutical commerce [1] Group 2 - On July 29, the stock experienced significant volatility, with a drop of over 2% within 5 minutes around 9:35 AM, followed by a rebound of over 2% shortly after at 9:41 AM, indicating active market trading [1] - The net outflow of main funds was 21.79 million yuan, accounting for 0.64% of the circulating market value, suggesting a certain degree of capital withdrawal [1]